BPG is committed to discovery and dissemination of knowledge
Systematic Reviews
Copyright: ©Author(s) 2026.
World J Meta-Anal. Sep 18, 2026; 14(3): 120937
Published online Sep 18, 2026. doi: 10.13105/wjma.120937
Figure 1
Figure 1 Mechanisms of anti-pruritic therapies. PXR: Pregnane X receptor; IBAT: Ileal bile acid transporter; PPAR: Peroxisome proliferator-activated receptor.
Figure 2
Figure 2  Preferred Reporting Items for Systematic reviews and Meta-Analyses flow diagram.
Figure 3
Figure 3 Diagnostic approach to cholestatic pruritus. NRS: Numerical Rating Scale; VAS: Visual Analogue Scale; GGT: Gamma-glutamyl transferase; RUQ: Right upper quadrant; US: Ultrasound; MRCP: Magnetic resonance cholangiopancreatography; ERCP: Endoscopic retrograde cholangiopancreatography; PSC: Primary sclerosing cholangitis; FIB-4: Fibrosis-4 index; APRI: Aspartate aminotransferase/platelet ratio index; ICP: Intrahepatic cholestasis of pregnancy.
Figure 4
Figure 4  Proposed multidisciplinary model of care.
Figure 5
Figure 5 Stepwise management algorithm for cholestatic pruritus. PBC: Primary biliary cholangitis; PSC: Primary sclerosing cholangitis; SSC: Secondary sclerosing cholangitis; IBAT: Ileal bile acid transporter; UVB: Ultraviolet B; PFIC: Progressive familial intrahepatic cholestasis; ICP: Intrahepatic cholestasis of pregnancy; UDCA: Ursodeoxycholic acid.


Write to the Help Desk